Texto: 
Asymptomatic right-sided abdominal mass.
6 weeks of neoadjuvant chemotherapy comprised of Vincristine, Dactinomycin, Doxorubicin (DD4A) followed by right nephrectomy.
‚Ä¢ Initial study:
- Large right-sided renal mass (12.2cm AP x 10.6cm Trans x 14.1cm CC). Predominantly hypodense w/ areas of heterogeneity.  Possible cystic degeneration along superior border.
- Classic ‚Äúclaw sign‚Äù demonstrating renal origination.
- Significant mass effect on liver, pancreas, and inferior vena cava.
- Non-opacification of right renal vein and mass effect on IVC limit evaluation for tumor thrombosis.
- Right lower lobe ground glass opacity (3mm x 5mm).  DDX includes metastatic, atelectasis, or infection.

‚Ä¢ After 6 weeks Doxorubicin (DD4A) therapy:
- Decrease in right renal mass size (7.3cm AP x 8.4cm Trans x 11.7cm CC).
- Increased calcification and heterogenicity of mass.
- Continued mass effect on liver, adjacent IVC, and right renal vein.
- IVC and right renal vein grossly patent.
- Resolution of previously noted right lower lobe lung mass.
- Internal reproductive organs within normal limits for age.
Wilms Tumor
‚Ä¢ Wilms Tumor
‚Ä¢ Neuroblastoma
‚Ä¢ Multilocular Cystic Nephroma
‚Ä¢ Mesoblastic nephroma
‚Ä¢ Renal cell carcinoma
30 month old girl with right-sided abdominal mass.
This case demonstrates the classic "claw sign" expected for tumor originating from the kidney.  Also demonstrated the significant mass effect that Wilms tumors can have on intra-abdominal organs and vessels.  Finally, benefits on neoadjuvant therapy was appreciated with decreased tumor burden prior to tumor removal.


Keywords: 
\-\ wilms\\ tumor\\ \\‚\\Ä\\¢\\ wilms\\ tumor\\ \\‚\\Ä\\¢\\ neuroblastoma\\ \\‚\\Ä\\¢\\ multilocular\\ cystic\\ nephroma\\ \\‚\\Ä\\¢\\ mesoblastic\\ nephroma\\ \\‚\\Ä\\¢\\ renal\\ cell\\ carcinoma\\ 30\\ month\\ old\\ girl\ \(0\)\
\-\ classic\\ \\‚\\Ä\\ú\\ claw\\ sign\\ \\‚\\Ä\\ù\\ demonstrating\\ renal\\ origination\ \(0\)\
\-\ possible\\ cystic\\ degeneration\\ along\\ superior\\ border\ \(0\)\
\-\ previously\\ noted\\ right\\ lower\\ lobe\\ lung\\ mass\ \(1\)\
\-\ right\\ lower\\ lobe\\ ground\\ glass\\ opacity\ \(0\)\
\-\ internal\\ reproductive\\ organs\\ within\\ normal\\ limits\ \(0\)\
\-\ right\\ renal\\ vein\\ grossly\\ patent\ \(1\)\
\-\ \\‚\\Ä\\¢\\ initial\\ study\ \(0\)\
\-\ decreased\\ tumor\\ burden\\ prior\ \(1\)\
\-\ right\\ renal\\ mass\\ size\ \(1\)\
\-\ wilms\\ tumors\ \(0\)\
\-\ \\‚\\Ä\\¢\ \(8449\)\
\-\ 6cm\\ trans\\ x\\ 14\ \(0\)\
\-\ 4cm\\ trans\\ x\\ 11\ \(0\)\
\-\ 3cm\\ ap\\ x\\ 8\ \(0\)\
\-\ 2cm\\ ap\\ x\\ 10\ \(0\)\
\-\ 3mm\\ x\\ 5mm\\ \\)\\.\ \(0\)\
\-\ right\\ renal\\ vein\ \(17\)\
\-\ sided\\ renal\\ mass\ \(1\)\
\-\ tumor\\ thrombosis\ \(1\)\
\-\ tumor\\ removal\ \(2\)\
\-\ tumor\\ originating\ \(1\)\
\-\ claw\\ sign\ \(11\)\
\-\ 7cm\\ cc\\ \\)\\.\ \(0\)\
\-\ 1cm\\ cc\\ \\)\\.\ \(0\)\
\-\ predominantly\\ hypodense\\ w\ \(0\)\
\-\ inferior\\ vena\\ cava\ \(54\)\
\-\ ddx\\ includes\\ metastatic\ \(0\)\
\-\ significant\\ mass\\ effect\ \(18\)\
\-\ continued\\ mass\\ effect\ \(0\)\
\-\ sided\\ abdominal\\ mass\ \(3\)\
\-\ neoadjuvant\\ chemotherapy\\ comprised\ \(1\)\
\-\ ivc\\ limit\\ evaluation\ \(0\)\
\-\ 6\\ weeks\\ doxorubicin\ \(0\)\
\-\ abdominal\\ organs\ \(12\)\
\-\ mass\\ effect\ \(295\)\
\-\ right\\ nephrectomy\ \(8\)\
\-\ large\\ right\ \(27\)\
\-\ asymptomatic\\ right\ \(1\)\
\-\ 6\\ weeks\ \(93\)\
\-\ classic\ \(290\)\
\-\ neoadjuvant\\ therapy\ \(1\)\
\-\ increased\\ calcification\ \(0\)\
\-\ case\\ demonstrates\ \(60\)\
\-\ also\\ demonstrated\ \(16\)\
\-\ adjacent\\ ivc\ \(0\)\
\-\ right\ \(7267\)\
\-\ mass\ \(4930\)\
\-\ ivc\ \(3\)\
\-\ doxorubicin\ \(13\)\
\-\ therapy\ \(1418\)\
\-\ vincristine\ \(19\)\
\-\ vessels\ \(266\)\
\-\ resolution\ \(197\)\
\-\ pancreas\ \(127\)\
\-\ opacification\ \(86\)\
\-\ non\ \(1889\)\
\-\ liver\ \(830\)\
\-\ kidney\ \(876\)\
\-\ intra\ \(1289\)\
\-\ infection\ \(713\)\
\-\ heterogenicity\ \(1\)\
\-\ heterogeneity\ \(12\)\
\-\ followed\ \(428\)\
\-\ finally\ \(9\)\
\-\ expected\ \(147\)\
\-\ decrease\ \(714\)\
\-\ dd4a\ \(0\)\
\-\ dactinomycin\ \(2\)\
\-\ benefits\ \(25\)\
\-\ atelectasis\ \(143\)\
\-\ areas\ \(516\)\
\-\ appreciated\ \(126\)\
\-\ age\ \(7354\)\
\-\ 7\ \(4391\)\
\-\ 12\ \(1027\)\
